AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02963454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan (0.2 μg/kg/min) will be used as indicated
Study NCT03526744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: marine protein hydrolysate 1234
Description: Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out.
Study NCT03526744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: marine protein hydrolysate 2134
Description: Dietary Supplement for e.g. in this order: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out.
Study NCT03526744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: marine protein hydrolysate 3124
Description: Dietary Supplement for e.g. in this order: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out.
Study NCT03526744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: marine protein hydrolysate 4123
Description: Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out.
Study NCT01307384 — intervention group
Intervention type: DEVICE
Intervention: Continuum Metal on Polyethylene Acetabular System
Description: Used in primary hip arthroplasty
Study NCT02585362 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: The standardized Training program will be performed twice a week in the Kantonsspital Winterthur and once a week in a home based setting
Study NCT02585362 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutrition counseling
Description: At least 3 times, participants will receive nutrition counseling to improve energy- and protein intake
Study NCT02585362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: whey protein supplement
Description: On workout days study participants will consume twice a day 15 g of the supplement powder with approximately 150 ml water. On the remaining days participants consume the supplement once a day.
Study NCT02536027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous venovenous hemofiltration
Description: Continuous renal replacement therapy (CRRT) has become routine for patients with AKI, chronic renal failure, ﬂuid overload as well as oliguria in ICU. In clinical practice, continuous venovenous hemofiltration (CVVH) is actually the method of choice for CRRT in critically ill and hemodynamic instable patients. CVVH has significant beneficial effects on removing inflammatory cytokines, improving oxygen index, decreasing vasopressor requirements, increasing cardiac index, and regulating immune dysfunction, specifically in patients with septic shock.
Study NCT01475877 — intervention group
Intervention type: DRUG
Intervention: Bromfenac
Description: Bromfenac 0.09% 1 drop in study eyes q day
Study NCT02848222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bruder Moist Heat Compress
Study NCT02848222 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Washcloth
Study NCT03601260 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Allopurinol
Description: Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
Study NCT02947386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02947386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Given IV
Study NCT00555724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB022
Description: IV infusion once every three weeks until disease progression or unacceptable toxicity
Study NCT04684394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM103
Description: GEM103 500 mcg/50 mcL intravitreal injection
Study NCT04684394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept 2 mg/50 mcL (SOC) intravitreal injection~Sham intravitreal injection
Study NCT02947386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT00027170 — intervention group
Intervention type: DEVICE
Intervention: Siemens MRI scanner
Description: Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
Study NCT01250106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: twice daily
Study NCT04684394 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept 2 mg/50 mcL (SOC) intravitreal injection~Sham intravitreal injection
Study NCT01250106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus reuteri
Description: twice daily
Study NCT03111563 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Warm saline distension media in office hysteroscopy
Description: warm saline distension media in office hysteroscopy
Study NCT00379665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
Study NCT04147689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DESIRIAL® PLUS
Description: DESIRIAL® PLUS is a cross-linked hyaluronic acid gel to restore volume by filling the labia majora, to rehydrate and to add tone and tension to the area of connective tissue.~The baseline injection is performed at V1, with a maximum volume to be injected per labium of 2 ml. The exact volume will be determined by the physician in order to reach optimal volume correction.~One optional touch-up injection of DESIRIAL® PLUS is allowed at V2 (4 weeks after Baseline), with a maximum volume to be injected per labium of 1 ml. No other touch-up injections are allowed until the end of the study.
Study NCT01205100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bio-feedback
Description: By providing on-line electromyography information of muscle activity, patients will be able to control and actively correct their muscle activity during the 15 min treatment session. Each patients will attend 3 treatment sessions.
Study NCT01205100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03579940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.
Study NCT03579940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT04519736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage
Study NCT02252146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400
Description: MO-8400 given subcutaneously twice weekly
Study NCT03065322 — intervention group
Intervention type: OTHER
Intervention: To assess risk of OSA
Description: The risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed. Study participants will be divided based on the results of the Berlin and ESS questionnaires and sleep studies into two groups: 1) PCOS low risk OSA: women with normal ESS and normal Berlin questionnaire (no sleep studies performed), or women with normal sleep studies; and 2) PCOS OSA: women with OSA proven by sleep studies.
Study NCT04314908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical enlargement
Description: The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will be opened. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary.
Study NCT04314908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical enlargement + Sonic Activation Assisted Irrigation
Description: The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary.
Study NCT04314908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Apical enlargement
Description: The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary.
Study NCT04314908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Apical enlargement + Sonic Activation Assisted Irrigation
Description: The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary.
Study NCT01038141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for advanced haemorrhoidal disease
Description: Milligan Morgan vs Recto Anal Repair
Study NCT04001413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0457
Description: MEDI0457 is an investigational drug that will be administered with the Cellectra Device in this study
Study NCT04001413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is an investigational drug in this study.
Study NCT03813888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arsha Vidya chldren's Group
Description: Yoga, Vedic chants, Vedant sessions, Gita sessions and group activities within the Gurukulam (centre)
Study NCT03813888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Activity group
Description: Usual after school activities at home.
Study NCT04290039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate Ophthalmic Solution
Description: Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP.
Study NCT04290039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulphate Injection
Description: Atropine sulfate injection, USP, 8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).
Study NCT01478971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin
Description: Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous \[IV\] or subcutaneous \[SC\]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of \<11 g/dL.
Study NCT01478971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginesatide
Description: Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at \<11 g/dL.
Study NCT02277600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068
Study NCT02277600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir
Study NCT02277600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Cobicistat
Study NCT01553903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen,
Description: Tamoxifen 20 mg/day during 5 years,
Study NCT01553903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25mg/day during 5 years
Study NCT01553903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole 1 mg/day during 5 years,
Study NCT01553903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg/day during 5 years,
Study NCT01132807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV
Study NCT01132807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01132807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine Hydrochloride
Description: Given PO
Study NCT01132807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV
Study NCT01132807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV
Study NCT01132807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01132807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Description: Given IV
Study NCT01132807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT01132807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04684394 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham intravitreal injection
Study NCT02368028 — intervention group
Intervention type: OTHER
Intervention: Oral Samples
Description: Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
Study NCT02648490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: recombinant human anti-EGFR monoclonal antibody against cancers
Study NCT01132807 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT
Study NCT01132807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FDG PET/CT
Study NCT01132807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study NCT00610402 — intervention group
Intervention type: OTHER
Intervention: blood sample tear drop sample
Description: blood sample tear drop sample
Study NCT05120427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid based nutrient Supplements (LNS):
Description: LNS are 20 g/\~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet.
Study NCT05120427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Growth Charts
Description: Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding.
Study NCT01689142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine new formulation (HOE901)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT01689142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT02911870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNAC
Description: Oral administration
Study NCT02911870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT02911870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration
Study NCT02911870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral administration
Study NCT02727218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest tube removal
Description: chest tube removal post thoracoscopic surgery
Study NCT02727218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube removal
Description: chest tube removal post thoracoscopic surgery
Study NCT03010527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab injections every four weeks (Q4W)
Study NCT03010527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo injections every four weeks (Q4W)
Study NCT01003847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate, fatty acid, placebo
Description: fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
Study NCT01599663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management algorithm
Description: The algorithm guide the clinicians to score ICU patients pain systematically with different pain assessment tools. The tools are the Numeric Rating Scale, Behavioral Pain Scale and Behavioral Pain Scale Non Intubated. The algorithm guide the clinicians to choose between the different pain assessment tools depending on the ICU patient's condition and ability to rate his own pain. Thereafter the algorithm guide the clinicians to treat pain depending on the pain intensity score.
Study NCT00481819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506MR
Description: oral
Study NCT00481819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral
Study NCT00481819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: oral
Study NCT00481819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: oral
Study NCT00481819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: oral
Study NCT00481819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: oral
Study NCT00481819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: oral
Study NCT00481819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: oral
Study NCT01841905 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Description: Observational Study
Study NCT02802839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Study NCT01529073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
Study NCT04208308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chia seeds supplementation (25 g)
Description: Dosage: 1 daily dose energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg